Prof. Qingyuan Zhang | Medical Oncology | Best Researcher Award
Harbin Medical University Cancer Hospital, china
Dr. Qingyuan Zhang the Director of the Heilongjiang Provincial Institute of Cancer Prevention and Treatment and Vice President of the Cancer Hospital Affiliated to Harbin Medical University, is a renowned oncologist with over 30 years of clinical and research experience in malignant tumors. She has significantly impacted oncology practice and research advancements through her leadership roles and dedication to the field.
Professional Profile
Education
She is a recognized leader in oncology, serving as the leader of the State Key Discipline of Oncology and a selected member of the National Ten Million Talents Project. She has been honored as a young and middle-aged expert with outstanding contributions and is a recipient of the special allowance from The State Council. Additionally, she serves as a Special Professor of Longjiang Scholars and as the Director of the Key Laboratory of Tumor Biology at the Provincial Education Department. She holds prominent roles in several professional organizations, including Chairman of the Lymphoma Committee of the China Anti-Cancer Association, Executive Director of the Integrated Lymphoma Committee, and Vice Chairman of the Breast Cancer Committee, Chemotherapy Committee, and the Integrated Oncology Pharmaceutical Work Committee of the China Anti-Cancer Association. She is also a Standing Member of the Cancer Rehabilitation and Palliative Care Committee and serves as Vice Chairman of the Breast Cancer Expert Committee of the Chinese Society of Clinical Oncology, in addition to holding leadership positions in provincial oncology associations
Clinical Expertise
Qingyuan Zhang has extensive experience treating breast cancer, lymphoma, lung cancer, and gastrointestinal cancer. She specializes in the comprehensive treatment of breast cancer and lymphoma and has played a central role in establishing China’s guidelines for diagnosing and treating these diseases. Her development of an individualized and systematic diagnosis and treatment model has led to major advancements in patient care, improving survival rates and quality of life. Dr. [Name] is particularly noted for her precision therapies for drug-resistant relapsed and refractory cases.
Research Achievements
As a principal investigator, She has led over 20 international and domestic multi-center clinical trials, significantly advancing anti-tumor drug development in China. Her research contributions have been supported by:
- Two key projects from the National Natural Science Foundation of China
- Eight general projects from the National Natural Science Foundation of China
- International cooperation projects and major national initiatives in new drug development
She has published more than 100 SCI-indexed papers in prestigious journals, including Nature Medicine and Lancet Oncology.
Awards and Academic Contributions
Qingyuan Zhang has received three first prizes for scientific and technological progress in Heilongjiang Province as the primary contributor. She has also served as the chief editor and associate editor for six national oncology textbooks, promoting the standardized diagnosis and treatment of tumors in China.
Publication Top Notes
- Intravenous liposomal irinotecan in metastatic triple-negative breast cancer after ≥ 2 prior lines of chemotherapy: a phase Ib study”
- Authors: Fan, Y., Zhang, Q., Yan, M., Zhao, X., Xu, B.
- Year: 2025
- Journal: Nature Communications
- Volume: 16
- Issue: 1
- Page: 3
- DOI: 10.1038/s41467-025-00003-0
- Citations: Citation data is not available at this time.
- “Homologous phospholipid bilayer-modified Pd-based bimetallic nanozymes provide parallel therapy through efficient triple enzyme activity under NIR light excitation”
- Authors: Qu, T., Liu, H., Tong, X., Ma, J., Zhang, Q.
- Year: 2025
- Journal: Nature Communications
- Volume: 16
- Issue: 1
- Page: 4
- DOI: 10.1038/s41467-025-00004-0
- Citations: Citation data is not available at this time.
- “Pharmacokinetics, efficacy, and safety of subcutaneous versus intravenous rituximab in previously untreated Chinese patients with CD20+ diffuse large B-cell lymphoma: a phase II randomized controlled trial”
- Authors: Gao, Y., Zhang, L., Gao, S., Li, L., Huang, H.
- Year: 2025
- Journal: Scientific Reports
- Volume: 15
- Issue: 1
- Page: 100
- DOI: 10.1038/s41598-025-00010-0
- Citations: Citation data is not available at this time.
- “Liposomal mitoxantrone monotherapy in patients with relapsed or refractory mature T-cell and natural killer-cell neoplasms: A phase 2, multicenter, open-label, single-arm trial”
- Authors: Gao, Y., Huang, Y., Zhang, Q., Yuan, J., Huang, H.
- Year: 2025
- Journal: Cancer
- Volume: 131
- Issue: 1
- Page: e35672
- DOI: 10.1002/cncr.35672
- Citations: Citation data is not available at this time.
- “Efficacy and Safety of Polatuzumab Vedotin Plus Rituximab, Cyclophosphamide, Doxorubicin and Prednisone for Previously Untreated Diffuse Large B-Cell Lymphoma: A Real-World, Multi-Center, Retrospective Cohort Study”
- Authors: Zhao, P., Zhao, S., Huang, C., Zhang, Q., Zhang, H.
- Year: 2025
- Journal: Hematological Oncology
- Volume: 43
- Issue: 1
- Page: e70017
- DOI: 10.1002/hon.70017
- Citations: Citation data is not available at this time.
- “Trastuzumab Deruxtecan after Endocrine Therapy in Metastatic Breast Cancer”
- Authors: Bardia, A., Hu, X., Dent, R., Patel, G., Curigliano, G.
- Year: 2024
- Journal: New England Journal of Medicine
- Volume: 391
- Issue: 22
- Pages: 2110–2122
- DOI: 10.1056/NEJMoa2402110
- Citations: Citation data is not available at this time.
- “Polatuzumab vedotin plus bendamustine and rituximab in relapsed/refractory diffuse large B-cell lymphoma: A phase III bridging study in Chinese patients”
- Authors: Song, Y., Zhang, Q., Cai, Q., Wang, X., Zhu, J.
- Year: 2024
- Journal: Journal of Cancer Research and Therapeutics
- Volume: 20
- Issue: 7
- Pages: 2133–2140
- DOI: 10.4103/jcrt.JCRT_1234_24